Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 18:48 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2 / Phase 3UnknownINTERVENTIONAL

Growth Hormone For Poor Ovarian Reserve Patients in ICSI Trials

ClinicalTrials.gov · NCT05602090 · Registry updated: 2023-04-28

Condition / research focus: Poor Ovarian Reserve
Sponsor: Beni-Suef University
Countries with listed sites: Egypt
Registry dates and results: Start: 2022-02-01. Completion: 2023-10-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

4 IU of recombinant GH (Somatotropin ) (drug) — also listed as: (Somatotropin )

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Beni-suef university
Banī Suwayf, Beni Suweif Governorate, Egypt
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

The Difference Between POSEIDON Group 3 and Group 4 as Regards IVF

ClinicalTrials.gov · NCT05778331 · Registry updated: 2023-03-21

Condition / research focus: Infertility, Female; IVF
Sponsor: Ain Shams University
Countries with listed sites: Egypt
Registry dates and results: Start: 2023-01-10. Completion: 2023-09 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Antagonist protocol for induction of ovulation (procedure)

Where the study takes place — 1 listed sites

Ain Shams University
Cairo, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Progesterone Levels During Ovulation and Luteal Phase

ClinicalTrials.gov · NCT05076981 · Registry updated: 2023-03-14

Condition / research focus: Infertility, Female
Sponsor: ART Fertility Clinics LLC
Countries with listed sites: United Arab Emirates
Registry dates and results: Start: 2021-09-23. Completion: 2021-12-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

human chorionic gonadotropin (drug) — also listed as: Ovitrelle

Where the study takes place — 1 listed sites

ART Fertility Clinics LLC
Abu Dhabi, United Arab Emirates
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Early Phase 1CompletedINTERVENTIONAL

Can Biotin Supplementation be Used to Mask hCG Abuse?

ClinicalTrials.gov · NCT05450900 · Registry updated: 2023-02-03

Condition / research focus: Healthy
Sponsor: Sports Medicine Research and Testing Laboratory
Countries with listed sites: United States
Registry dates and results: Start: 2022-10-27. Completion: 2023-02-02 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Choriogonadotropin Alpha (drug) — also listed as: ovidrel, hCG
biotin (dietary_supplement) — also listed as: vitamin B7
Microcellulose filler (other) — also listed as: placebo, capsules

Where the study takes place — 1 listed sites

Sports Medicine Research and Testing Laboratory
Salt Lake City, Utah, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Anti-Müllerian Hormone (AMH) Measured With Fully Automated Assay Versus AFC in the Prediction of Ovarian Response

ClinicalTrials.gov · NCT04168892 · Registry updated: 2023-02-01

Condition / research focus: Ovarian Response
Sponsor: Andros Day Surgery Clinic
Countries with listed sites: Italy
Registry dates and results: Start: 2019-09-20. Completion: 2023-01-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

150 IU of HMG in patients with age ≤ 35 years (drug)
225 IU of HMG in patients with age > 35 years (drug)

Where the study takes place — 1 listed sites

ANDROS Day Surgery Clinic, Reproductive Medicine Unit
Palermo, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2WithdrawnINTERVENTIONAL

Clinical Research Study to Learn About the Effect and Safety of Different Doses of FE 999302 When Given as a Single Dose for Final Development of the Eggs After Ovarian Stimulation

ClinicalTrials.gov · NCT05571111 · Registry updated: 2023-01-09

Condition / research focus: Infertility
Sponsor: Ferring Pharmaceuticals
Countries with listed sites: Spain
Registry dates and results: Start: 2022-10-04. Completion: 2024-06-25 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

FE 999302 (drug) — also listed as: recombinant hCG
Ovitrelle (drug)
Novarel (drug)

Where the study takes place — 3 listed sites

Ferring Investigational Site
Madrid, Spain
Site recruitment: Not reported
Ferring Investigational Site
Seville, Spain
Site recruitment: Not reported
Ferring Investigational Site
Valencia, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Dual Ovarian Stimulation (DUOSTIM) for Poor Ovarian Responders

ClinicalTrials.gov · NCT03803228 · Registry updated: 2022-12-07

Condition / research focus: Fertility Disorders
Sponsor: Centre Hospitalier Intercommunal Creteil
Countries with listed sites: France
Registry dates and results: Start: 2018-09-03. Completion: 2021-11-24 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

DUOSTIM (drug) — also listed as: Same monthly cycle
Conventional stimuli (drug) — also listed as: Two different menstrual cycles

Where the study takes place — 4 listed sites

Polyclinique Jean Villar
Bruges, France
Site recruitment: Not reported
CHI Creteil
Créteil, France
Site recruitment: Not reported
Cabinet Médical Carré Saint Giniez
Marseille, France
Site recruitment: Not reported
Polyclinique Saint Roch
Montpellier, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Is in Vitro Maturation of Oocytes Influenced by the Origin of Gonadotropins Used in Maturation Medium: is There a Difference in Efficiency When Using Urinary Versus Recombinant Produced Follicle Stimulating Hormone and Human Chorionic Gonadotropin

ClinicalTrials.gov · NCT05370794 · Registry updated: 2022-11-07

Condition / research focus: In Vitro Maturation of Oocytes
Sponsor: Universitair Ziekenhuis Brussel
Countries with listed sites: Belgium
Registry dates and results: Start: 2022-04-19. Completion: 2023-06-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

rhCG= Ovitrelle®, 250g/0.5ml = 26000IU/ml, Merck-Serono (drug)
rFSH = Gonal F®, 300IU/0.5ml, Merck-Serono (drug)

Where the study takes place — 1 listed sites

UZ Brussel
Brussels, Belgium
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Sperm Retrieval Rates in Non-obstructive Azoospermic Men Subjected to Gonadotropin Therapy

ClinicalTrials.gov · NCT05110391 · Registry updated: 2022-11-03

Condition / research focus: Non-obstructive Azoospermia; Hormone Deficiency; Hypogonadism, Male; Male Infertility
Sponsor: ANDROFERT - Clinica de Andrologia e Reproducao Humana
Countries with listed sites: Brazil
Registry dates and results: Start: 2014-02-01. Completion: 2021-09-15 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Hormonal Therapy Agent (drug) — also listed as: recombinant human chorionic gonadotropin, recombinant FSH

Where the study takes place — 1 listed sites

Androfert
Campinas, São Paulo, Brazil
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effect of Intrauterine Injection of Hcg Before ET on Clinical Outcomes in IVF/ICSI Cycles

ClinicalTrials.gov · NCT03238807 · Registry updated: 2022-09-28

Condition / research focus: Infertility; ART
Sponsor: Assiut University
Countries with listed sites: Egypt
Registry dates and results: Start: 2018-07-08. Completion: 2020-10-04 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Human Chorionic Gonadotropin (drug) — also listed as: Epifasi

Where the study takes place — 1 listed sites

Assiut University - Women's Health Hospital
Asyut, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Frozen Embryo Transfer Pregnancy Outcomes Prediction by Microbiome and Transcriptome

ClinicalTrials.gov · NCT05545631 · Registry updated: 2022-09-19

Condition / research focus: Infertility; Microbiome
Sponsor: Shengjing Hospital
Countries with listed sites: China
Registry dates and results: Start: 2022-09-01. Completion: 2024-09-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

no intervention (other)

Where the study takes place — 1 listed sites

Xiuxia Wang
Shenyang, Liaoning, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Frozen Embryo Transfer Pregnancy Outcomes Prediction by Microbiome

ClinicalTrials.gov · NCT05521295 · Registry updated: 2022-09-19

Condition / research focus: Infertility; Microbiome
Sponsor: Shengjing Hospital
Countries with listed sites: China
Registry dates and results: Start: 2022-09-01. Completion: 2024-09-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

no intervention (other)

Where the study takes place — 1 listed sites

Xiuxia Wang
Shenyang, Liaoning, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Administration of Human Chorionic Gonadotrophin Before Secretory Transformation of Frozen-thawed Embryo Transfer Cycles

ClinicalTrials.gov · NCT05340010 · Registry updated: 2022-09-01

Condition / research focus: hCG; FET; Frozen-thawed Embryo Transfe; Human Chorionic Gonadotrophin
Sponsor: Alexandria University
Countries with listed sites: Egypt
Registry dates and results: Start: 2020-01-01. Completion: 2022-07-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Human Chorionic Gonadotrophin Intramuscular injection 10.000 IU (drug)

Where the study takes place — 1 listed sites

Alexandria university
Alexandria, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

hCG Priming in Women With Low Ovarian Reserve

ClinicalTrials.gov · NCT04643925 · Registry updated: 2022-08-25

Condition / research focus: Infertility, Female; Ovarian Reserve; In Vitro Fertilization
Sponsor: Copenhagen University Hospital, Rigshospitalet
Countries with listed sites: Denmark
Registry dates and results: Start: 2020-12-27. Completion: 2021-08-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ovitrelle (drug)

Where the study takes place — 1 listed sites

Rigshospitalet
København Ø, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4TerminatedINTERVENTIONAL

Type of Gonadotropin and Embryo Kinetics of Development

ClinicalTrials.gov · NCT02402192 · Registry updated: 2022-08-11

Condition / research focus: Infertility
Sponsor: IVI Madrid
Countries with listed sites: No country reported
Registry dates and results: Start: 2015-04. Completion: 2016-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Corifollitropin alfa (drug) — also listed as: Elonva

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

IVF Treatment in Women With Immature Oocytes in Previous Cycle

ClinicalTrials.gov · NCT02368964 · Registry updated: 2022-06-24

Condition / research focus: Infertility
Sponsor: Sheba Medical Center
Countries with listed sites: Israel
Registry dates and results: Start: 2015-02-01. Completion: 2020-06-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GnRH agonist 0.2 mg + hCG 250 mcg (drug) — also listed as: GnRH agonist - Decapeptyl , hCG - Ovitrelle
high dose hCG 500 mcg (drug) — also listed as: Ovitrelle

Where the study takes place — 1 listed sites

Sheba Medical Center
Ramat Gan, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Follicle Size and Oocyte Development

ClinicalTrials.gov · NCT03660813 · Registry updated: 2022-06-24

Condition / research focus: IVF Treatment
Sponsor: Sheba Medical Center
Countries with listed sites: Israel
Registry dates and results: Start: 2018-07-01. Completion: 2021-08-01 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Follicle measurment (diagnostic_test)
Ovitrelle ( Hcg 250 mcg) (drug)
Decapeptyl ( GnRH Agonist 0.1 mg*2 ) (drug)

Where the study takes place — 1 listed sites

Sheba Medical Center
Ramat Gan, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3UnknownINTERVENTIONAL

COMPARING TWO PROTOCOLS FOR FINAL OOCYTE MATURATION IN POOR RESPONDERS UNDERGOING GnRH-ANTAGONIST ICSI CYCLES

ClinicalTrials.gov · NCT05397795 · Registry updated: 2022-05-31

Condition / research focus: Infertility
Sponsor: Alexandria University
Countries with listed sites: No country reported
Registry dates and results: Start: 2022-06-01. Completion: 2023-01-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

10000 IU hCG (Choriomon5000 IU; IBSA) (drug) — also listed as: CHORIONIC GONADOTROPHIN 5000 U
Triptorelin 0.2 mg (Decapeptyl 0.1 mg; Ferring) (drug) — also listed as: TRIPTOFEM 0.1 mg

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Relationship Between Some Vitamins and Antioxidants With in Vitro Fertilization Outcomes

ClinicalTrials.gov · NCT05393011 · Registry updated: 2022-05-26

Condition / research focus: In Vitro Fertilization; Infertility
Sponsor: Damascus University
Countries with listed sites: Syria
Registry dates and results: Start: 2017-08-20. Completion: 2021-08-15 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

human chorionic gonadotropin (drug) — also listed as: Chorex

Where the study takes place — 2 listed sites

Damascus University
Damascus, Syria
Site recruitment: Not reported
Orient Hospital
Damascus, Syria
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Administration of Follicle-stimulating Hormone (FSH) and Low Dose Human Chorionic Gonadotropin (hCG) for Oocyte Maturity While Decreasing hCG Exposure in In Vitro Fertilization (IVF) Cycles

ClinicalTrials.gov · NCT02310919 · Registry updated: 2022-04-29

Condition / research focus: Infertility
Sponsor: University of California, San Francisco
Countries with listed sites: United States
Registry dates and results: Start: 2014-09. Completion: 2018-06-20 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Low dose hCG plus FSH co-trigger (drug)
Standard dose of hCG (drug)

Where the study takes place — 1 listed sites

University of California at San Francisco
San Francisco, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 18:48 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2 / Phase 3UnknownINTERVENTIONAL

Growth Hormone For Poor Ovarian Reserve Patients in ICSI Trials

ClinicalTrials.gov · NCT05602090 · Registry updated: 2023-04-28

Condition / research focus: Poor Ovarian Reserve
Sponsor: Beni-Suef University
Countries with listed sites: Egypt
Registry dates and results: Start: 2022-02-01. Completion: 2023-10-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

4 IU of recombinant GH (Somatotropin ) (drug) — also listed as: (Somatotropin )

Where the study takes place — 1 listed sites

Beni-suef university
Banī Suwayf, Beni Suweif Governorate, Egypt
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

The Difference Between POSEIDON Group 3 and Group 4 as Regards IVF

ClinicalTrials.gov · NCT05778331 · Registry updated: 2023-03-21

Condition / research focus: Infertility, Female; IVF
Sponsor: Ain Shams University
Countries with listed sites: Egypt
Registry dates and results: Start: 2023-01-10. Completion: 2023-09 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Antagonist protocol for induction of ovulation (procedure)

Where the study takes place — 1 listed sites

Ain Shams University
Cairo, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Progesterone Levels During Ovulation and Luteal Phase

ClinicalTrials.gov · NCT05076981 · Registry updated: 2023-03-14

Condition / research focus: Infertility, Female
Sponsor: ART Fertility Clinics LLC
Countries with listed sites: United Arab Emirates
Registry dates and results: Start: 2021-09-23. Completion: 2021-12-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

human chorionic gonadotropin (drug) — also listed as: Ovitrelle

Where the study takes place — 1 listed sites

ART Fertility Clinics LLC
Abu Dhabi, United Arab Emirates
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Early Phase 1CompletedINTERVENTIONAL

Can Biotin Supplementation be Used to Mask hCG Abuse?

ClinicalTrials.gov · NCT05450900 · Registry updated: 2023-02-03

Condition / research focus: Healthy
Sponsor: Sports Medicine Research and Testing Laboratory
Countries with listed sites: United States
Registry dates and results: Start: 2022-10-27. Completion: 2023-02-02 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Choriogonadotropin Alpha (drug) — also listed as: ovidrel, hCG
biotin (dietary_supplement) — also listed as: vitamin B7
Microcellulose filler (other) — also listed as: placebo, capsules

Where the study takes place — 1 listed sites

Sports Medicine Research and Testing Laboratory
Salt Lake City, Utah, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Anti-Müllerian Hormone (AMH) Measured With Fully Automated Assay Versus AFC in the Prediction of Ovarian Response

ClinicalTrials.gov · NCT04168892 · Registry updated: 2023-02-01

Condition / research focus: Ovarian Response
Sponsor: Andros Day Surgery Clinic
Countries with listed sites: Italy
Registry dates and results: Start: 2019-09-20. Completion: 2023-01-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

150 IU of HMG in patients with age ≤ 35 years (drug)
225 IU of HMG in patients with age > 35 years (drug)

Where the study takes place — 1 listed sites

ANDROS Day Surgery Clinic, Reproductive Medicine Unit
Palermo, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2WithdrawnINTERVENTIONAL

Clinical Research Study to Learn About the Effect and Safety of Different Doses of FE 999302 When Given as a Single Dose for Final Development of the Eggs After Ovarian Stimulation

ClinicalTrials.gov · NCT05571111 · Registry updated: 2023-01-09

Condition / research focus: Infertility
Sponsor: Ferring Pharmaceuticals
Countries with listed sites: Spain
Registry dates and results: Start: 2022-10-04. Completion: 2024-06-25 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

FE 999302 (drug) — also listed as: recombinant hCG
Ovitrelle (drug)
Novarel (drug)

Where the study takes place — 3 listed sites

Ferring Investigational Site
Madrid, Spain
Site recruitment: Not reported
Ferring Investigational Site
Seville, Spain
Site recruitment: Not reported
Ferring Investigational Site
Valencia, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Dual Ovarian Stimulation (DUOSTIM) for Poor Ovarian Responders

ClinicalTrials.gov · NCT03803228 · Registry updated: 2022-12-07

Condition / research focus: Fertility Disorders
Sponsor: Centre Hospitalier Intercommunal Creteil
Countries with listed sites: France
Registry dates and results: Start: 2018-09-03. Completion: 2021-11-24 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

DUOSTIM (drug) — also listed as: Same monthly cycle
Conventional stimuli (drug) — also listed as: Two different menstrual cycles

Where the study takes place — 4 listed sites

Polyclinique Jean Villar
Bruges, France
Site recruitment: Not reported
CHI Creteil
Créteil, France
Site recruitment: Not reported
Cabinet Médical Carré Saint Giniez
Marseille, France
Site recruitment: Not reported
Polyclinique Saint Roch
Montpellier, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Is in Vitro Maturation of Oocytes Influenced by the Origin of Gonadotropins Used in Maturation Medium: is There a Difference in Efficiency When Using Urinary Versus Recombinant Produced Follicle Stimulating Hormone and Human Chorionic Gonadotropin

ClinicalTrials.gov · NCT05370794 · Registry updated: 2022-11-07

Condition / research focus: In Vitro Maturation of Oocytes
Sponsor: Universitair Ziekenhuis Brussel
Countries with listed sites: Belgium
Registry dates and results: Start: 2022-04-19. Completion: 2023-06-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

rhCG= Ovitrelle®, 250g/0.5ml = 26000IU/ml, Merck-Serono (drug)
rFSH = Gonal F®, 300IU/0.5ml, Merck-Serono (drug)

Where the study takes place — 1 listed sites

UZ Brussel
Brussels, Belgium
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Sperm Retrieval Rates in Non-obstructive Azoospermic Men Subjected to Gonadotropin Therapy

ClinicalTrials.gov · NCT05110391 · Registry updated: 2022-11-03

Condition / research focus: Non-obstructive Azoospermia; Hormone Deficiency; Hypogonadism, Male; Male Infertility
Sponsor: ANDROFERT - Clinica de Andrologia e Reproducao Humana
Countries with listed sites: Brazil
Registry dates and results: Start: 2014-02-01. Completion: 2021-09-15 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Hormonal Therapy Agent (drug) — also listed as: recombinant human chorionic gonadotropin, recombinant FSH

Where the study takes place — 1 listed sites

Androfert
Campinas, São Paulo, Brazil
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effect of Intrauterine Injection of Hcg Before ET on Clinical Outcomes in IVF/ICSI Cycles

ClinicalTrials.gov · NCT03238807 · Registry updated: 2022-09-28

Condition / research focus: Infertility; ART
Sponsor: Assiut University
Countries with listed sites: Egypt
Registry dates and results: Start: 2018-07-08. Completion: 2020-10-04 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Human Chorionic Gonadotropin (drug) — also listed as: Epifasi

Where the study takes place — 1 listed sites

Assiut University - Women's Health Hospital
Asyut, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Frozen Embryo Transfer Pregnancy Outcomes Prediction by Microbiome and Transcriptome

ClinicalTrials.gov · NCT05545631 · Registry updated: 2022-09-19

Condition / research focus: Infertility; Microbiome
Sponsor: Shengjing Hospital
Countries with listed sites: China
Registry dates and results: Start: 2022-09-01. Completion: 2024-09-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

no intervention (other)

Where the study takes place — 1 listed sites

Xiuxia Wang
Shenyang, Liaoning, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Frozen Embryo Transfer Pregnancy Outcomes Prediction by Microbiome

ClinicalTrials.gov · NCT05521295 · Registry updated: 2022-09-19

Condition / research focus: Infertility; Microbiome
Sponsor: Shengjing Hospital
Countries with listed sites: China
Registry dates and results: Start: 2022-09-01. Completion: 2024-09-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

no intervention (other)

Where the study takes place — 1 listed sites

Xiuxia Wang
Shenyang, Liaoning, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Administration of Human Chorionic Gonadotrophin Before Secretory Transformation of Frozen-thawed Embryo Transfer Cycles

ClinicalTrials.gov · NCT05340010 · Registry updated: 2022-09-01

Condition / research focus: hCG; FET; Frozen-thawed Embryo Transfe; Human Chorionic Gonadotrophin
Sponsor: Alexandria University
Countries with listed sites: Egypt
Registry dates and results: Start: 2020-01-01. Completion: 2022-07-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Human Chorionic Gonadotrophin Intramuscular injection 10.000 IU (drug)

Where the study takes place — 1 listed sites

Alexandria university
Alexandria, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

hCG Priming in Women With Low Ovarian Reserve

ClinicalTrials.gov · NCT04643925 · Registry updated: 2022-08-25

Condition / research focus: Infertility, Female; Ovarian Reserve; In Vitro Fertilization
Sponsor: Copenhagen University Hospital, Rigshospitalet
Countries with listed sites: Denmark
Registry dates and results: Start: 2020-12-27. Completion: 2021-08-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ovitrelle (drug)

Where the study takes place — 1 listed sites

Rigshospitalet
København Ø, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4TerminatedINTERVENTIONAL

Type of Gonadotropin and Embryo Kinetics of Development

ClinicalTrials.gov · NCT02402192 · Registry updated: 2022-08-11

Condition / research focus: Infertility
Sponsor: IVI Madrid
Countries with listed sites: No country reported
Registry dates and results: Start: 2015-04. Completion: 2016-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Corifollitropin alfa (drug) — also listed as: Elonva

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

IVF Treatment in Women With Immature Oocytes in Previous Cycle

ClinicalTrials.gov · NCT02368964 · Registry updated: 2022-06-24

Condition / research focus: Infertility
Sponsor: Sheba Medical Center
Countries with listed sites: Israel
Registry dates and results: Start: 2015-02-01. Completion: 2020-06-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GnRH agonist 0.2 mg + hCG 250 mcg (drug) — also listed as: GnRH agonist - Decapeptyl , hCG - Ovitrelle
high dose hCG 500 mcg (drug) — also listed as: Ovitrelle

Where the study takes place — 1 listed sites

Sheba Medical Center
Ramat Gan, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Follicle Size and Oocyte Development

ClinicalTrials.gov · NCT03660813 · Registry updated: 2022-06-24

Condition / research focus: IVF Treatment
Sponsor: Sheba Medical Center
Countries with listed sites: Israel
Registry dates and results: Start: 2018-07-01. Completion: 2021-08-01 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Follicle measurment (diagnostic_test)
Ovitrelle ( Hcg 250 mcg) (drug)
Decapeptyl ( GnRH Agonist 0.1 mg*2 ) (drug)

Where the study takes place — 1 listed sites

Sheba Medical Center
Ramat Gan, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3UnknownINTERVENTIONAL

COMPARING TWO PROTOCOLS FOR FINAL OOCYTE MATURATION IN POOR RESPONDERS UNDERGOING GnRH-ANTAGONIST ICSI CYCLES

ClinicalTrials.gov · NCT05397795 · Registry updated: 2022-05-31

Condition / research focus: Infertility
Sponsor: Alexandria University
Countries with listed sites: No country reported
Registry dates and results: Start: 2022-06-01. Completion: 2023-01-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

10000 IU hCG (Choriomon5000 IU; IBSA) (drug) — also listed as: CHORIONIC GONADOTROPHIN 5000 U
Triptorelin 0.2 mg (Decapeptyl 0.1 mg; Ferring) (drug) — also listed as: TRIPTOFEM 0.1 mg

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Relationship Between Some Vitamins and Antioxidants With in Vitro Fertilization Outcomes

ClinicalTrials.gov · NCT05393011 · Registry updated: 2022-05-26

Condition / research focus: In Vitro Fertilization; Infertility
Sponsor: Damascus University
Countries with listed sites: Syria
Registry dates and results: Start: 2017-08-20. Completion: 2021-08-15 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

human chorionic gonadotropin (drug) — also listed as: Chorex

Where the study takes place — 2 listed sites

Damascus University
Damascus, Syria
Site recruitment: Not reported
Orient Hospital
Damascus, Syria
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Administration of Follicle-stimulating Hormone (FSH) and Low Dose Human Chorionic Gonadotropin (hCG) for Oocyte Maturity While Decreasing hCG Exposure in In Vitro Fertilization (IVF) Cycles

ClinicalTrials.gov · NCT02310919 · Registry updated: 2022-04-29

Condition / research focus: Infertility
Sponsor: University of California, San Francisco
Countries with listed sites: United States
Registry dates and results: Start: 2014-09. Completion: 2018-06-20 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Low dose hCG plus FSH co-trigger (drug)
Standard dose of hCG (drug)

Where the study takes place — 1 listed sites

University of California at San Francisco
San Francisco, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →